Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group announced that its Vonoprazan Fumarate Tablets have received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in digestive system therapies, offering a novel treatment option with advantages over conventional proton pump inhibitors, potentially strengthening its market position.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development and production of drugs. It is known for its innovative approach in creating therapeutic products, particularly in the area of digestive system treatments.
YTD Price Performance: 20.11%
Average Trading Volume: 143,556,278
Technical Sentiment Signal: Buy
Current Market Cap: HK$66B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.